2023, Volume 20, Issue 1
Engineering >> 2023, Volume 20, Issue 1 doi: 10.1016/j.eng.2021.09.007
Multimodal Identification by Transcriptomics and Multiscale Bioassays of Active Components in Xuanfeibaidu Formula to Suppress Macrophage-Mediated Immune Response
a Pharmaceutical Informatics Institute, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China
b State Key Laboratory of Component-Based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
# These authors contributed equally to this paper.
Next Previous
Abstract
Xuanfeibaidu Formula (XFBD) is a Chinese medicine used in the clinical treatment of coronavirus disease 2019 (COVID-19) patients. Although XFBD has exhibited significant therapeutic efficacy in clinical practice, its underlying pharmacological mechanism remains unclear. Here, we combine a comprehensive research approach that includes network pharmacology, transcriptomics, and bioassays in multiple model systems to investigate the pharmacological mechanism of XFBD and its bioactive substances. High-resolution mass spectrometry was combined with molecular networking to profile the major active substances in XFBD. A total of 154 compounds were identified or tentatively characterized, including flavonoids, terpenes, carboxylic acids, and other types of constituents. Based on the chemical composition of XFBD, a network pharmacology-based analysis identified inflammation-related pathways as primary targets. Thus, we examined the anti-inflammation activity of XFBD in a lipopolysaccharide-induced acute inflammation mice model. XFBD significantly alleviated pulmonary inflammation and decreased the level of serum proinflammatory cytokines. Transcriptomic profiling suggested that genes related to macrophage function were differently expressed after XFBD treatment. Consequently, the effects of XFBD on macrophage activation and mobilization were investigated in a macrophage cell line and a zebrafish wounding model. XFBD exerts strong inhibitory effects on both macrophage activation and migration. Moreover, through multimodal screening, we further identified the major components and compounds from the different herbs of XFBD that mediate its anti-inflammation function. Active components from XFBD, including Polygoni cuspidati Rhizoma, Phragmitis Rhizoma, and Citri grandis Exocarpium rubrum, were then found to strongly downregulate macrophage activation, and polydatin, isoliquiritin, and acteoside were identified as active compounds. Components of Artemisiae annuae Herba and Ephedrae Herba were found to substantially inhibit endogenous macrophage migration, while the presence of ephedrine, atractylenolide, and kaempferol was attributed to these effects. In summary, our study explores the pharmacological mechanism and effective components of XFBD in inflammation regulation via multimodal approaches, and thereby provides a biological illustration of the clinical efficacy of XFBD.
Keywords
Xuanfeibaidu Formula ; Multimodal identification ; Inflammation ; Macrophage activation ; Macrophage migration
SupplementaryMaterials
Figures
Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
References
[ 1 ] Asselah T, Durantel D, Pasmant E, Lau G, Schinazi RF. COVID-19: discovery, diagnostics and drug development. J Hepatol 2021;74(1):168–84. link1
[ 2 ] Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 2021;19(3):141–54. link1
[ 3 ] Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 2021;184(4):861–80. link1
[ 4 ] www.who.int [Internet]. Geneva: World Health Organization; 2021 [cited 2021 Sep 22]. Available from: https://covid19.who.int.
[ 5 ] Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395(10229):1033–4. link1
[ 6 ] Wang Y, Li X, Zhang JH, Xue R, Qian JY, Zhang XH, et al. Mechanism of Xuanfei Baidu Tang in treatment of COVID-19 based on network pharmacology. China J Chin Mater Med 2020;45(10):2249–56. Chinese. link1
[ 7 ] Xiong WZ, Wang G, Du J, Ai W. Efficacy of herbal medicine (Xuanfei Baidu decoction) combined with conventional drug in treating COVID-19: a pilot randomized clinical trial. Integr Med Res 2020;9(3):100489. link1
[ 8 ] Pluskal T, Castillo S, Villar-Briones A, Oresic M. MZmine 2: modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinf 2010;11:395. link1
[ 9 ] Myers OD, Sumner SJ, Li S, Barnes S, Du X. One step forward for reducing false positive and false negative compound identifications from mass spectrometry metabolomics data: new algorithms for constructing extracted ion chromatograms and detecting chromatographic peaks. Anal Chem 2017;89 (17):8696–703. link1
[10] Wang M, Carver JJ, Phelan VV, Sanchez LM, Garg N, Peng Y, et al. Sharing and community curation of mass spectrometry data with Global Natural Products Social Molecular Networking. Nat Biotechnol 2016;34(8):828–37. link1
[11] Andonegui G, Kerfoot SM, McNagny K, Ebbert KV, Patel KD, Kubes P. Platelets express functional Toll-like receptor-4. Blood 2005;106(7):2417–23. link1
[12] Wessels I, Pupke JT, von Trotha KT, Gombert A, Himmelsbach A, Fischer HJ, et al. Zinc supplementation ameliorates lung injury by reducing neutrophil recruitment and activity. Thorax 2020;75(3):253–61. link1
[13] Andonegui G, Bonder CS, Green F, Mullaly SC, Zbytnuik L, Raharjo E, et al. Endothelium-derived Toll-like receptor-4 is the key molecule in LPS-induced neutrophil sequestration into lungs. J Clin Invest 2003;111(7):1011–20. link1
[14] Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc Ser B 1995;57 (1):289–300. link1
[15] Wang S, Wang H, Liu Y, Wang Y, Fan X, Cheng Y. Rapid discovery and identification of anti-inflammatory constituents from traditional Chinese medicine formula by activity index, LC-MS, and NMR. Sci Rep 2016;6 (1):31000. link1
[16] Ellett F, Pase L, Hayman JW, Andrianopoulos A, Lieschke GJ. mpeg1 promoter transgenes direct macrophage-lineage expression in zebrafish. Blood 2011;117(4):e49–56. link1
[17] Hall C, Flores MV, Storm T, Crosier K, Crosier P. The zebrafish lysozyme C promoter drives myeloid-specific expression in transgenic fish. BMC Dev Biol 2007;7(1):42. link1
[18] Westerfield M. A guide for the laboratory use of zebrafish (Danio rerio). In: Westerfield M, editor. The zebrafish book. Eugene: University of Oregon Press; 2000. link1
[19] Yu Y, Chen J, Zhang X, Wang Y, Wang S, Zhao L, et al. Identification of antiinflammatory compounds from Zhongjing formulae by knowledge mining and high-content screening in a zebrafish model of inflammatory bowel diseases. Chin Med 2021;16(1):42. link1
[20] Xie Y, Tolmeijer S, Oskam JM, Tonkens T, Meijer AH, Schaaf MJM. Glucocorticoids inhibit macrophage differentiation towards a proinflammatory phenotype upon wounding without affecting their migration. Dis Model Mech 2019;12(5):dmm037887.
[21] Hu W, van Steijn L, Li C, Verbeek FJ, Cao Lu, Merks RMH, et al. A novel function of TLR2 and MyD88 in the regulation of leukocyte cell migration behavior during wounding in zebrafish larvae. Front Cell Dev Biol 2021;9:624571. link1
[22] Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010;140(6):805–20. link1
[23] Rovas A, Osiaevi I, Buscher K, Sackarnd J, Tepasse PR, Fobker M, et al. Microvascular dysfunction in COVID-19: the MYSTIC study. Angiogenesis 2021;24(1):145–57. link1
[24] Jeon JW, Jung JG, Shin EC, Choi HI, Kim HY, Cho ML, et al. Soluble CD93 induces differentiation of monocytes and enhances TLR responses. J Immunol 2010;185(8):4921–7. link1
[25] Greenlee MC, Sullivan SA, Bohlson SS. Detection and characterization of soluble CD93 released during inflammation. Inflamm Res 2009;58 (12):909–19. link1
[26] Wang H, Zhu J, Liu Z, Lv H, Lv P, Chen F, et al. Silencing of long isoforms of nuclear factor erythroid 2 like 1 primes macrophages towards M1 polarization. Free Radic Biol Med 2018;117:37–44. link1
[27] Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of doublestranded RNA and activation of NF-jB by Toll-like receptor 3. Nature 2001;413 (6857):732–8. link1
[28] Ting Tan RS, Lin B, Liu Q, Tucker-Kellogg L, Ho B, Leung BPL, et al. The synergy in cytokine production through MyD88-TRIF pathways is co-ordinated with ERK phosphorylation in macrophages. Immunol Cell Biol 2013;91(5):377–87. link1
[29] Nguyen-Chi M, Laplace-Builhe B, Travnickova J, Luz-Crawford P, Tejedor G, Phan QT, et al. Identification of polarized macrophage subsets in zebrafish. eLife 2015;4:e07288.
[30] Kim HS, Asmis R. Mitogen-activated protein kinase phosphatase 1 (MKP-1) in macrophage biology and cardiovascular disease. A redox-regulated master controller of monocyte function and macrophage phenotype. Free Radic Biol Med 2017;109:75–83. link1
[31] Nakata S, Tsutsui M, Shimokawa H, Tamura M, Tasaki H, Morishita T, et al. Vascular neuronal NO synthase is selectively upregulated by platelet-derived growth factor: involvement of the MEK/ERK pathway. Arterioscler Thromb Vasc Biol 2005;25(12):2502–8. link1
[32] Muniyappa H, Das KC. Activation of c-Jun N-terminal kinase (JNK) by widely used specific p38 MAPK inhibitors SB202190 and SB203580: a MLK-3-MKK7- dependent mechanism. Cell Signal 2008;20(4):675–83. link1
[33] Guo M, Härtlova A, Gierlin´ ski M, Prescott A, Castellvi J, Losa JH, et al. Triggering MSR1 promotes JNK-mediated inflammation in IL-4-activated macrophages. EMBO J 2019;38(11):e100299. link1
[34] Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of COVID-19—preliminary report. N Engl J Med 2020;383(19):1813–36. link1
[35] Liu J, Cao R, Xu M, Wang Xi, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020;6(1):16. link1
[36] Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 2020;382(19):1787–99. link1
[37] Ledford H. Coronavirus breakthrough: dexamethasone is first drug shown to save lives. Nature 2020;582(7813):469.
[38] Vinetz JM. Lack of efficacy of hydroxychloroquine in COVID-19. BMJ 2020;369: m2018. link1
[39] Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al.; RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med 2021;384(8):693–704. link1
[40] Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol 2020;20 (6):363–74. link1
[41] Montón C, Ewig S, Torres A, El-Ebiary M, Filella X, Rañó A, et al. Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Eur Respir J 1999;14(1):218–20. link1
[42] Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020;395(10223):473–5. link1
[43] Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Forthal DN. Pharmacoimmunomodulatory therapy in COVID-19. Drugs 2020;80(13):1267–92. link1
[44] Yao XH, Li TY, He ZC, Ping YF, Liu HW, Yu SC, et al. A pathological report of three COVID-19 cases by minimally invasive autopsies. Chin J Pathol 2020;49 (5):411–7. link1
[45] Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature 2013;496(7446):445–55. link1
[46] Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Esmaeili SA, Mardani F, et al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol 2018;233(9):6425–40. link1
[47] Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). MedRxiv 2020. link1
[48] Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med 2018;24(6):739–48. link1
[49] Crayne CB, Albeituni S, Nichols KE, Cron RQ. The immunology of macrophage activation syndrome. Front Immunol 2019;10:119. link1
[50] Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. Microbiol Mol Biol Rev 2012;76(1):16–32. link1
[51] www.gov.cn [Internet]. Beijing: The State Council of the People’s Republic of China; 2020 [cited 2021 Sep 22]. Available from: http://english.www.gov.cn/ news/topnews/202003/23/content_WS5e787a9dc6d0c201c2cbf3b4.html.
[52] Yang Q, Sun Q, Jiang B, Xu H, Luo M, Xie P, et al. Retrospective clinical study on treatment of COVID-19 patients with integrated traditional Chinese and western medicine. Chin Tradit Herb Drugs 2020;51(8):2050–4. Chinese. link1
[53] Peng W, Qin R, Li X, Zhou H. Botany, phytochemistry, pharmacology, and potential application of Polygonum cuspidatum Sieb.et Zucc.: a review. J Ethnopharmacol 2013;148(3):729–45. link1
[54] Park SJ, Kim YW, Park MK, Byun SH, Kim SC, Lee JR. Anti-inflammatory steroid from Phragmitis Rhizoma modulates LPS-mediated signaling through inhibition of NF-jB pathway. Inflammation 2016;39(2):727–34. link1
[55] Jiang K, Song Q, Wang L, Xie T, Wu X, Wang P, et al. Antitussive, expectorant and anti-inflammatory activities of different extracts from Exocarpium Citri grandis. J Ethnopharmacol 2014;156:97–101. link1
[56] Yuan YP, Zhai HQ, Guo ZJ, Kong LT, Jia XY, Wang NN, et al. Analysis of historical origin and standardization system construction of Citri Grandis Exocarpium. China J Chin Mater Med 2017;42(11):2214–8. Chinese. link1
[57] Lou T, Jiang W, Xu D, Chen T, Fu Y. Inhibitory effects of polydatin on lipopolysaccharide-stimulated RAW 264.7 cells. Inflammation 2015;38 (3):1213–20. link1
[58] Liu YY, Wu JQ, Fan RY, He ZH, Li CY, He MF. Isoliquiritin promote angiogenesis by recruiting macrophages to improve the healing of zebrafish wounds. Fish Shellfish Immunol 2020;100:238–45. link1
[59] Wang R, Zhang CY, Bai LP, Pan HD, Shu LM, Kong AN, et al. Flavonoids derived from liquorice suppress murine macrophage activation by up-regulating heme oxygenase-1 independent of Nrf2 activation. Int Immunopharmacol 2015;28 (2):917–24. link1
[60] Kim JY, Park SJ, Yun KJ, Cho YW, Park HJ, Lee KT. Isoliquiritigenin isolated from the roots of Glycyrrhiza uralensis inhibits LPS-induced iNOS and COX-2 expression via the attenuation of NF-jB in RAW 264.7 macrophages. Eur J Pharmacol 2008;584(1):175–84. link1
[61] Zheng Y, Guo Z, He W, Yang Y, Li Y, Zheng A, et al. Ephedrine hydrochloride protects mice from LPS challenge by promoting IL-10 secretion and inhibiting proinflammatory cytokines. Int Immunopharmacol 2012;13(1):46–53. link1
[62] Wang A, Xiao Z, Zhou L, Zhang J, Li X, He Q. The protective effect of atractylenolide I on systemic inflammation in the mouse model of sepsis created by cecal ligation and puncture. Pharm Biol 2016;54(1):146–50. link1
[63] Ren J, Lu Y, Qian Y, Chen B, Wu T, Ji G. Recent progress regarding kaempferol for the treatment of various diseases. Exp Ther Med 2019;18(4):2759–76. link1
京公网安备 11010502051620号
